Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.

Serova M, Tijeras-Raballand A, Dos Santos C, Martinet M, Neuzillet C, Lopez A, Mitchell DC, Bryan BA, Gapihan G, Janin A, Bousquet G, Riveiro ME, Bieche I, Faivre S, Raymond E, de Gramont A.

Oncotarget. 2016 Jun 21;7(25):38467-86. doi: 10.18632/oncotarget.9542.

2.

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.

Serova M, Tijeras-Raballand A, Dos Santos C, Albuquerque M, Paradis V, Neuzillet C, Benhadji KA, Raymond E, Faivre S, de Gramont A.

Oncotarget. 2015 Aug 28;6(25):21614-27.

3.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.

Dos Santos C, Tijeras-Raballand A, Serova M, Sebbagh S, Slimane K, Faivre S, de Gramont A, Raymond E.

Br J Cancer. 2015 Jan 6;112(1):86-94. doi: 10.1038/bjc.2014.578. Epub 2014 Nov 25.

4.

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S, Raymond E.

Eur J Cancer. 2014 Sep;50(14):2463-77. doi: 10.1016/j.ejca.2014.06.015. Epub 2014 Jul 16.

PMID:
25042151
5.

Benzofuran derivatives as anticancer inhibitors of mTOR signaling.

Salomé C, Ribeiro N, Chavagnan T, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L.

Eur J Med Chem. 2014 Jun 23;81:181-91. doi: 10.1016/j.ejmech.2014.05.014. Epub 2014 May 5.

PMID:
24836070
6.

Cancer wars: natural products strike back.

Basmadjian C, Zhao Q, Bentouhami E, Djehal A, Nebigil CG, Johnson RA, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry LG.

Front Chem. 2014 May 1;2:20. doi: 10.3389/fchem.2014.00020. eCollection 2014. Review.

7.

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.

Salomé C, Narbonne V, Ribeiro N, Thuaud F, Serova M, de Gramont A, Faivre S, Raymond E, Désaubry L.

Eur J Med Chem. 2014 Mar 3;74:41-9. doi: 10.1016/j.ejmech.2013.12.020. Epub 2014 Jan 2.

PMID:
24445311
8.

Unraveling galectin-1 as a novel therapeutic target for cancer.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S.

Cancer Treat Rev. 2014 Mar;40(2):307-19. doi: 10.1016/j.ctrv.2013.07.007. Epub 2013 Aug 1. Review.

PMID:
23953240
9.

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E.

Mar Drugs. 2013 Mar 20;11(3):944-59. doi: 10.3390/md11030944.

10.

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.

Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.

Cancer Chemother Pharmacol. 2013 May;71(5):1297-307. doi: 10.1007/s00280-013-2129-6. Epub 2013 Mar 12.

PMID:
23479136
11.

Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.

Albert S, Riveiro ME, Halimi C, Hourseau M, Couvelard A, Serova M, Barry B, Raymond E, Faivre S.

Head Neck. 2013 Dec;35(12):1819-28. doi: 10.1002/hed.23217. Epub 2013 Mar 6. Review.

PMID:
23468253
12.

Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.

Tijeras-Raballand A, Neuzillet C, Couvelard A, Serova M, de Gramont A, Hammel P, Raymond E, Faivre S.

Target Oncol. 2012 Sep;7(3):173-81. doi: 10.1007/s11523-012-0229-6. Epub 2012 Aug 25. Review.

PMID:
22923165
13.

Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.

Albert S, Hourseau M, Halimi C, Serova M, Descatoire V, Barry B, Couvelard A, Riveiro ME, Tijeras-Raballand A, de Gramont A, Raymond E, Faivre S.

Oral Oncol. 2012 Dec;48(12):1263-71. doi: 10.1016/j.oraloncology.2012.06.010. Epub 2012 Jul 7.

PMID:
22776129
14.

Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH.

J Med Chem. 2012 Jun 14;55(11):5121-9. doi: 10.1021/jm300014q. Epub 2012 May 30.

15.

Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.

Lovejoy KS, Serova M, Bieche I, Emami S, D'Incalci M, Broggini M, Erba E, Gespach C, Cvitkovic E, Faivre S, Raymond E, Lippard SJ.

Mol Cancer Ther. 2011 Sep;10(9):1709-19. doi: 10.1158/1535-7163.MCT-11-0250. Epub 2011 Jul 12.

16.

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S.

Target Oncol. 2011 Jun;6(2):119-24. doi: 10.1007/s11523-011-0177-6. Epub 2011 Apr 28. Review.

PMID:
21533544
17.

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

Serova M, Bieche I, Sablin MP, Pronk GJ, Vidaud M, Cvitkovic E, Faivre S, Raymond E.

Br J Cancer. 2011 Jan 18;104(2):272-80. doi: 10.1038/sj.bjc.6606063. Epub 2010 Dec 21.

18.

Antisense inhibition of amphiregulin expression reduces EGFR phosphorylation in transformed human breast epithelial cells.

Ma L, Huet E, Serova M, Berthois Y, Calvo F, Mourah S, Menashi S.

Anticancer Res. 2010 Jun;30(6):2101-6.

PMID:
20651357
19.

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E.

Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Review.

PMID:
20569080
20.

Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.

Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA, Emami S, Vidaud D, Hammel P, Theou-Anton N, Gespach C, Faivre S, Raymond E.

Mol Cancer Ther. 2010 May;9(5):1308-17. doi: 10.1158/1535-7163.MCT-10-0167. Epub 2010 Apr 20.

21.

Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.

Ghoul A, Serova M, Astorgues-Xerri L, Bieche I, Bousquet G, Varna M, Vidaud M, Phillips E, Weill S, Benhadji KA, Lokiec F, Cvitkovic E, Faivre S, Raymond E.

Cancer Res. 2009 May 15;69(10):4260-9. doi: 10.1158/0008-5472.CAN-08-2837. Epub 2009 May 5.

22.

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.

Benhadji KA, Serova M, Ghoul A, Cvitkovic E, Le Tourneau C, Ogbourne SM, Lokiec F, Calvo F, Hammel P, Faivre S, Raymond E.

Br J Cancer. 2008 Dec 2;99(11):1808-15. doi: 10.1038/sj.bjc.6604642.

23.

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

Le Tourneau C, Faivre S, Serova M, Raymond E.

Br J Cancer. 2008 Oct 21;99(8):1197-203. doi: 10.1038/sj.bjc.6604636. Epub 2008 Sep 16. Review.

24.

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.

Serova M, Ghoul A, Benhadji KA, Faivre S, Le Tourneau C, Cvitkovic E, Lokiec F, Lord J, Ogbourne SM, Calvo F, Raymond E.

Mol Cancer Ther. 2008 Apr;7(4):915-22. doi: 10.1158/1535-7163.MCT-07-2060.

25.

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.

Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S.

Cancer Chemother Pharmacol. 2008 Jul;62(2):305-13. Epub 2007 Oct 2.

PMID:
17912526
26.

Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.

Serova M, Galmarini CM, Ghoul A, Benhadji K, Green SR, Chiao J, Faivre S, Cvitkovic E, Le Tourneau C, Calvo F, Raymond E.

Br J Cancer. 2007 Sep 3;97(5):628-36. Epub 2007 Jul 17.

27.

Preclinical and clinical development of novel agents that target the protein kinase C family.

Serova M, Ghoul A, Benhadji KA, Cvitkovic E, Faivre S, Calvo F, Lokiec F, Raymond E.

Semin Oncol. 2006 Aug;33(4):466-78. Review.

PMID:
16890801
28.

[Amphiregulin antisense RNA expression inhibits angiogenesis of human breast cancer in nude mice].

Ma L, Serova M, Podgorniak MP, Berthois Y, Mourah S, Calvo F.

Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):521-3. Chinese.

PMID:
16438846
29.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
30.
31.

[The importance of Holter ECG monitoring in the diagnosis of latent arrhythmias in patients with acute respiratory viral infections].

Mol'kova TN, Bogomolov BP, Deviatkin AV, Serova MV.

Ter Arkh. 1991;63(9):30-2. Russian.

PMID:
1759217
32.

[Hybridoma technology: review of patent information].

Serova MA, Rybal'skiĭ NG.

Zh Mikrobiol Epidemiol Immunobiol. 1989 Jun;(6):114-24. Review. Russian. No abstract available.

PMID:
2678839
33.

[Physical rehabilitation of patients with diabetes mellitus and obesity at the hospital stage using therapeutic gymnastics in a pool and on training equipment].

Bulavin AM, Maslova GI, Smirnova OI, Serova MV, Asadchikh IN.

Vopr Kurortol Fizioter Lech Fiz Kult. 1986 Mar-Apr;(2):44-5. Russian. No abstract available.

PMID:
3716259
34.
36.

Improved injection needles.

Serov VA, Serova MA, Surkov VP, Kalinin VP, Kabanov KI, Kruglov VN.

Biomed Eng (NY). 1968 Nov-Dec;2(6):358-60. No abstract available.

PMID:
5760748
37.

[Roentgenological research of the gallbladder in polyclinical conditions].

KHOMIAKOV IuS, SEROVA MN.

Sov Med. 1960 Oct;24:135-7. Russian. No abstract available.

PMID:
13755741

Supplemental Content

Loading ...
Support Center